Rasoul S, Svilaas T, Ottervanger J-P, Timmer J R, van 't Hof A W J, Zijlstra F
Neth Heart J. 2006 Jan;14(1):19-23.
To review the currently available data to investigate the clinical benefit of high- and low-dose glucose-insulin-potassium (GIK) in patients with ST-segment elevation acute myocardial infarction (STEMI).
Quantitative analysis of all randomised trials on GIK in patients with STEMI. Electronic and manual searches for randomised controlled trials of GIK in STEMI were performed with regard to inclusion criteria, dose of GIK and additional use of reperfusion therapy, and a meta-analysis with the primary endpoint 30-day mortality was performed.
Data from 16 randomised trials, involving 26,273 patients, were included.
Studies were conducted between 1962 and 2005. Overall, hospital mortality was 9.6% after GIK compared with 10.2% in controls (p=0.088). GIK infusion was not associated with an increase in major adverse events.
This quantitative analysis of GIK in patients with STEMI did not show a beneficial or detrimental effect of GIK infusion on 30-day mortality. GIK infusion should not be part of the standard therapy for patients with STEMI.
回顾现有数据，以研究高剂量和低剂量葡萄糖 - 胰岛素 - 钾（GIK）对ST段抬高型急性心肌梗死（STEMI）患者的临床益处。
对所有关于STEMI患者GIK的随机试验进行定量分析。针对纳入标准、GIK剂量和再灌注治疗的额外使用情况，对STEMI患者GIK的随机对照试验进行了电子和人工检索，并对主要终点30天死亡率进行了荟萃分析。
纳入了16项随机试验的数据，涉及26273名患者。
研究在1962年至2005年期间进行。总体而言，GIK治疗后医院死亡率为9.6%，而对照组为10.2%（p = 0.088）。GIK输注与主要不良事件增加无关。
对STEMI患者GIK的这项定量分析未显示GIK输注对30天死亡率有有益或有害影响。GIK输注不应成为STEMI患者标准治疗的一部分。
